Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots. Also Read: 8 Covid Vaccines Aim to Cover Every Indian by Year-end: What Are They & How They Work There were 77 cases of
Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.
There were 77 cases of COVID-19, 14 in the group that got the vaccine and the rest were in volunteers who received dummy shots. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
The vaccine was similarly effective against several variants including the one first detected in the U.K. that’s dominant in the U.S.
The US-based Novavax plans to produce its two-shot vaccine at eight manufacturing locations, including the Serum Institute of India. With Novavax, SII will produce 20 crore Covid-19 vaccines for India by the year-end.
Comment List